501 related articles for article (PubMed ID: 27809799)
1. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
[TBL] [Abstract][Full Text] [Related]
2. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus.
Valour F; Karsenty J; Bouaziz A; Ader F; Tod M; Lustig S; Laurent F; Ecochard R; Chidiac C; Ferry T;
Antimicrob Agents Chemother; 2014; 58(2):746-55. PubMed ID: 24247130
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus.
Vaudaux P; Ferry T; Uçkay I; François P; Schrenzel J; Harbarth S; Renzoni A
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3367-74. PubMed ID: 22833247
[TBL] [Abstract][Full Text] [Related]
5. [Problems with teicoplanin in the treatment of osteoarticular infections caused by methicillin-resistant S. aureus].
Gómez J; Climent C; Herrero F; Ruano L
Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):567-8. PubMed ID: 1489810
[No Abstract] [Full Text] [Related]
6. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
[TBL] [Abstract][Full Text] [Related]
7. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
Pensotti C; Nacinovich F; Vidiella G; Carbone E; Marin M; Di Stéfano C; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
[TBL] [Abstract][Full Text] [Related]
8. Is Intraarticular Antibiotic Administration Effective in the Treatment of Methicillin-Resistant Staphylococcus aureus?
Kuyucu E; Çabuk H; Güler Y; Çabuk F; Kiliç E; Bülbül M
Acta Chir Orthop Traumatol Cech; 2019; 86(4):276-280. PubMed ID: 31524589
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
10. Long-term intramuscular teicoplanin treatment of chronic osteomyelitis due to oxacillin-resistant Staphylococcus aureus in outpatients.
Testore GP; Uccella I; Sarrecchia C; Mattei A; Impagliazzo A; Sordillo P; Andreoni M
J Chemother; 2000 Oct; 12(5):412-5. PubMed ID: 11128561
[TBL] [Abstract][Full Text] [Related]
11. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
Huang JH; Hsu RB
Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of MRSA infections].
Borde JP; Kern WV
Dtsch Med Wochenschr; 2012 Dec; 137(49):2553-7. PubMed ID: 23143638
[No Abstract] [Full Text] [Related]
13. Epidemiology and risk factors of Staphylococcus aureus CC398 bone and joint infections.
Bouiller K; Hocquet D; Sauget M; Bertrand X; Chirouze C
BMC Infect Dis; 2020 May; 20(1):384. PubMed ID: 32471442
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
[TBL] [Abstract][Full Text] [Related]
15. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis.
Graninger W; Wenisch C; Wiesinger E; Menschik M; Karimi J; Presterl E
Eur J Clin Microbiol Infect Dis; 1995 Jul; 14(7):643-7. PubMed ID: 7588858
[TBL] [Abstract][Full Text] [Related]
16. Pristinamycin in the treatment of MSSA bone and joint infection.
Valour F; Boibieux A; Karsenty J; Vallat MP; Braun E; Perpoint T; Biron F; Laurent F; Lustig S; Chidiac C; Ferry T;
J Antimicrob Chemother; 2016 Apr; 71(4):1063-70. PubMed ID: 26801082
[TBL] [Abstract][Full Text] [Related]
17. Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections.
Tascini C; Tagliaferri E; Di Paolo A; Ciofi L; Del Tacca M; Lambelet P; Menichetti F
J Chemother; 2009 Aug; 21(4):421-5. PubMed ID: 19622461
[TBL] [Abstract][Full Text] [Related]
18. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
Zeckel ML
J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
[TBL] [Abstract][Full Text] [Related]
19. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
[TBL] [Abstract][Full Text] [Related]
20. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
